Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or even a loyal Reddit fanbase.
While momentum can be a leading indicator, it has burned many investors as it doesn’t always correlate with long-term success. Keeping that in mind, here is one stock with lasting competitive advantages and two that may correct.
Two Momentum Stocks to Sell:
Teradyne (TER)
One-Month Return: +22.9%
Sporting most major chip manufacturers as its customers, Teradyne (NASDAQ: TER) is a US-based supplier of automated test equipment for semiconductors as well as other technologies and devices.
Why Is TER Not Exciting?
- Muted 3.4% annual revenue growth over the last five years shows its demand lagged behind its semiconductor peers
- Estimated sales growth of 17.3% for the next 12 months implies demand will slow from its two-year trend
- 10.7 percentage point decline in its free cash flow margin over the last five years reflects the company’s increased investments to defend its market position
At $440.50 per share, Teradyne trades at 64.3x forward P/E. To fully understand why you should be careful with TER, check out our full research report (it’s free).
Fortune Brands (FBIN)
One-Month Return: +12.4%
Targeting a wide customer base of residential and commercial customers, Fortune Brands (NYSE: FBIN) makes plumbing, security, and outdoor living products.
Why Is FBIN Risky?
- Absence of organic revenue growth over the past two years suggests it may have to lean into acquisitions to drive its expansion
- Sales are projected to tank by 1.2% over the next 12 months as its demand continues evaporating
- Earnings per share have dipped by 6% annually over the past five years, which is concerning because stock prices follow EPS over the long term
Fortune Brands is trading at $42.31 per share, or 12.9x forward P/E. Read our free research report to see why you should think twice about including FBIN in your portfolio.
One Momentum Stock to Buy:
Hims & Hers Health (HIMS)
One-Month Return: +48.4%
Originally launched with a focus on stigmatized conditions like hair loss and sexual health, Hims & Hers Health (NYSE: HIMS) operates a consumer-focused telehealth platform that connects patients with healthcare providers for prescriptions and wellness products.
Why Is HIMS a Good Business?
- Business is winning new contracts that can potentially increase in value as its customer base averaged 26.1% growth over the past two years
- Free cash flow margin jumped by 16.1 percentage points over the last five years, giving the company more resources to pursue growth initiatives, repurchase shares, or pay dividends
- Improving returns on capital suggest its past investments are beginning to deliver value
Hims & Hers Health’s stock price of $35.25 implies a valuation ratio of 2.7x forward price-to-sales. Is now a good time to buy? Find out in our full research report, it’s free.
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
